Accessibility Menu
Grifols logo

Grifols(NASDAQ) GRFS

Market Cap$2.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+38%
5 Year-45%
1 Year-18%
1 Month-0%
Premium Feature
Moneyball Superscore
57/100
$7.84
+1.42%
+0.11Today
After hours$7.84+$0.00 (+0.00%)
Grifols last closing stock price
MetricPriceDate
Last closeUSD 7.832026-09-02
Grifols stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.89%USD 7.902026-08-26
1 month-0.38%USD 7.862026-08-03
3 month+4.87%USD 7.472026-06-04
Year to date-14.99%USD 9.212025-12-31
1 year-17.88%USD 9.542025-09-02
3 year-13.92%USD 9.102023-09-01
5 year-45.09%USD 14.262021-09-03
Since inception+37.91%USD 5.682011-06-02

Grifols Financials at a Glance

Market Cap

$2.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€7.43B

Net Income (TTM)

€452.49M

EPS (TTM)

$0.77

P/E Ratio

10.10

Dividend

$0.00

Beta (Volatility)

0.81 (Low)

Price

$7.84

Volume

261,702.788

Open

$7.71

Previous Close

$7.83

Daily Range

$7.70 - $7.85

52-Week Range

$6.96 - $10.23

Estimated Earnings Date

Nov 10, 2026

GRFS News

Physician monitoring patients onscreen vitals

Why Shares of Grifols Were Up Tuesday

James HalleyMay 9, 2023
medical staff talk with management

2 Healthcare Stocks That Could Help Make You a Fortune

Alex CarchidiFeb 8, 2022
A medical professional using a microscope

Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study

Eric VolkmanAug 5, 2020
GettyImages-1216432083

Better Coronavirus Stock: Grifols or Novartis?

Alex CarchidiJun 19, 2020
Plasma donation

Who Can Donate Plasma for COVID-19 Patients?

Brian Orelli, PhDJun 14, 2020
GettyImages-1063275556

Is Rigel Pharmaceuticals Stock a Buy?

David HaenDec 11, 2019

Is This Overlooked Stock Primed for More Growth?

Stephen D. SimpsonMar 25, 2014

3 Stocks Set to Beat the S&P Today

Karl LoomesJul 24, 2012
Page 1

GRFS: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grifols

Grifols, S.A. is a global healthcare company based in Barcelona, Spain, specializing in the development, manufacture, and distribution of therapeutic products derived from human plasma. Founded in 1940, Grifols operates across multiple divisions, focusing on innovative treatments for chronic and life-threatening conditions.

Products and Services
  • Plasma-derived medicines, including immunoglobulins and clotting factors
  • Non-biological pharmaceuticals and medical devices
  • Diagnostic products for disease prevention and monitoring
Growth Outlook
  • Revenue increased to €1.87 billion in Q2 2026, reflecting strong demand
  • TTM revenue of €7.4 billion indicates consistent growth trajectory
  • Expansion in emerging markets supports long-term growth potential
Financial Highlights
  • Net income of €154 million in Q2 2026, up from €74 million in Q1 2026
  • Operating income margin improved to 17.6% in Q2 2026
  • TTM P/E ratio of 14.56 suggests attractive valuation compared to industry peers
Grifols, S.A. has established itself as a leader in the healthcare sector, particularly in plasma-derived therapies. The company's diverse product offerings cater to a wide range of medical needs, enhancing its market position. Recent financial performance demonstrates a robust growth trajectory, with significant revenue increases and improved profitability margins. The company's strategic focus on expanding into emerging markets further supports its long-term growth outlook. Investors may find Grifols an appealing option within the healthcare industry, given its solid financial foundation and commitment to innovation.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25,258

CEO

Nacho Abia Buenache, MBA

Website

www.grifols.com

Headquarters

Barcelona, CT 08174, ES

GRFS Financials

Key Financial Metrics (TTM)

Gross Margin

37.23%

Operating Margin

16.66%

Net Income Margin

6.09%

Return on Equity

8.43%

Return on Capital

8.47%

Return on Assets

2.25%

Earnings Yield

9.90%

Dividend Yield

0.00%

Payout Ratio

28.31%

Stock Overview

Market Cap

$2.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

258.22M

Volume

261.70K

Avg. Volume

619.39K

Financials (TTM)

Gross Profit

€2.77B

Operating Income

€1.24B

EBITDA

€1.75B

Operating Cash Flow

€1.10B

Capital Expenditure

-€376.06M

Free Cash Flow

€719.02M

Cash & ST Invst.

€529.00M

Total Debt

€8.52B

Grifols Performance Analysis

Grifols annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 6,373,073,5749.3%
20232023-12-31EUR 7,126,689,18911.8%
20242024-12-31EUR 7,801,566,9409.5%
20252025-12-31EUR 8,491,420,5008.8%
Grifols sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.4%
Q42025-12-315.2%
Q12026-03-31-12.0%
Q22026-06-308.5%
Grifols annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.32-1.9%
20232023-12-31EUR 0.07-79.1%
20242024-12-31EUR 0.25270.2%
20252025-12-31EUR 0.67167.2%
Grifols sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3011.8%
Q42025-12-31-26.3%
Q12026-03-31-21.4%
Q22026-06-30109.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.87B

-0.9%

Gross Profit

€704.00M

-5.4%

Gross Margin

37.57%

N/A

Market Cap

$2.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$80.05K

N/A

Employees

25,258

N/A

Net Income

€154.00M

+31.6%

EBITDA

€535.00M

+54.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€529.00M

-6.5%

Total Debt

€8.52B

-3.4%

Accounts Receivable

€1.19B

-5.1%

Inventory

€3.49B

+4.3%

Long Term Debt

€8.10B

-3.9%

Short Term Debt

€420.00M

+6.6%

Return on Assets

2.25%

N/A

Return on Invested Capital

6.93%

N/A

Free Cash Flow

€108.00M

+13.7%

Operating Cash Flow

€227.00M

+46.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATRAptarGroup, Inc.
$130.33-0.45%
MASIMasimo Corporation
$179.95+0.00%
AVTRAvantor, Inc.
$14.65+3.17%
HSICHenry Schein, Inc.
$90.39+2.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$224.41+0.03%
PCGPG&E
$13.33-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.37+0.00%
NUNu Holdings
$15.40+0.07%

Questions About GRFS

What is the current price of Grifols?

Grifols is trading at $7.83 per share.

What is the 52-week range for Grifols?

Over the past 52 weeks, Grifols has traded between $6.96 and $10.23.

How much debt does Grifols have?

As of the most recent reporting period, Grifols reported total debt of €9.74B.

How much cash does Grifols have on hand?

Grifols reported €586.51M in cash and cash equivalents in its most recent financial results.

What is Grifols’s dividend yield?

Grifols does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services